Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide

Prostate

Volumn 48, Issue 3, 2001, Pages 188-199

  Rekasi, Zoltan ^b   Schally, Andrew V ^b   Plonowski, Artur ^a   Czompoly, Tamas ^a   Csernus, Balazs ^b   Varga, Jozsef L ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgens; Growth hormone releasing hormone; Progression; Prostate cancer; Prostate specific antigen; Tumor therapy; Vasoactive intestinal peptide

Indexed keywords

ADENYLATE CYCLASE ACTIVATOR; ANDROGEN; FORSKOLIN; GROWTH HORMONE RELEASING FACTOR INHIBITOR; HORMONE INHIBITOR; JV 1 38; JV 1 53; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL SECRETION; CELL STIMULATION; CONTROLLED STUDY; DEPOLARIZATION; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; ANIMALS; CYCLIC AMP; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH HORMONE-RELEASING HORMONE; MALE; MICE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0034898083     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.1097     Document Type: Article

References (42)

1. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
2. Prostate-specific antigen: Its usefulness in clinical medicine
3. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer
4. Prostate antigen: A marker for human prostate epithelial cells
5. Prostate-specific antigen in milk of lactating women
6. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium
7. Prostate specific antigen expression by various tumors
8. Prognostic value of prostate-specific antigen for women with breast cancer: A large United States cohort study
9. Human prostate-specific antigen: Structural and functional similarity with serine protease
10. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen
11. Prostate specific antigen role and function
12. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma
13. Mitogenic response of osteoblast cells to prostate-specific antigen suggest an activation of latent TGF-Beta and a proteolytic modulation of cell adhesion receptors
14. New biological functions of prostate-specific antigen?
15. The biosynthesis and secretion of prostate-specific antigen in LNCaP cells
16. Antiangiogenic activity of prostate-specific antigen
17. Vasoactive intestinal peptide stimulates prostate-specific antigen secretion by LNCaP prostate cancer cells
18. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone
19. The human prostate gland: A histochemical and immunohistochemical study of neuropeptides, serotonin, dopamine beta-hydroxylase and acetylcholinesterase in autonomic nerves and ganglia
20. Neuroendocrine peptides in the prostate
21. In vitro identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging
22. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate
23. Type 1 vasoactive intestinal peptide receptor expression in PC3/AR cells is evidence of prostate epithelial differentiation
24. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: Evidence from in vitro studies on human prostatic and pancreatic cancers
25. Vasoactive intestinal peptide: Biologic role in health and disease
26. Modulation of cyclic AMP and inositol phosphate production in rat prostatic cultures by VIP/PACAP, ATP and carbachol. Role in prostatic proliferation
27. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells
28. Growth hormone releasing hormone (GHRH) and GHRH receptor expression in prostate cancer cell lines
29. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone
30. Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers
31. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities
32. Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro
33. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay
34. The dispersed cell superfusion system
35. A method for evaluation of activity of antagonistic analogs of growth hormone-releasing hormone in a superfusion system
36. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
37. Molecular cloning of human prostate specific antigen cDNA
38. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: Quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction
39. Antagonistic analogs of growth hormone-releasing hormone (GH-RH): New potential antitumor agents
40. Prostate-specific antigen expression is regulated by an upstream enhancer
41. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter
42. Protein secretion and secretory processes in male accessory sex glands